The committee's recommendation was based on data from the TROPION-Breast01 trial, which also supported the US approval of Datroway in January.

The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Earnings season is now well under way, with a number of major companies due to release results in the coming week. Investors ...

The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

AstraZeneca and Daiichi Sankyo ’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster ...

Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.